Benign Prostatic Hyperplasia (BPH)

DBCOND0033444Urogenital Diseases

Benign Prostatic Hyperplasia (BPH) is the indication for 13 drugs in DrugBank. It is covered by 17 curated, structured indications.

Also known as
BPH · Prostatic Hypertrophy, Benign · Benign Prostatic Hypertrophy · Benign Prostatic Hyperplasia · Benign Prostate Hypertrophy
Classified under
Indicated drugs

Resolves to

Vocabularies
MeSHM0489822ICD-10N40SNOMED CT155906003MedDRA10004446UMLSC0426732

What you can answer from here — as of November 15, 2026

13Indicated drugsWith each drug's targets and mechanism
Listed above
17Structured indicationsPopulation, line of therapy, route and combination as fields, not prose
Sign in
255Clinical trialsPhase, status and sponsor resolved per trial
Sign in
11Drugs reporting it as an adverse effectWith incidence where the label states it
Sign in

Which approved drugs for Benign Prostatic Hyperplasia (BPH) share a target, and which companies have late-stage candidates against it?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In